Patient preference of ranibizumab treatment regimen for neovascular age-related macular degeneration -monthly injections versus pro re nata

详细信息    查看全文

• 作者：Katharina M. Droege (1)
  Albert Caramoy (1)
  Andreas Kersten (2)
  Janina Luberichs-Fauser (2)
  Katharina Zilkens (2)
  Dirk Müller (3)
  Bernd Kirchhof (1)
  Sascha Fauser (1)
  
• 关键词：Age ; related macular degeneration ; Ranibizumab ; Healthcare research
• 刊名：Graefe's Archive for Clinical and Experimental Ophthalmology
• 出版年：2014
• 出版时间：January 2014
• 年：2014
• 卷：252
• 期：1
• 页码：31-34
• 全文大小：110 KB
• 作者单位：Katharina M. Droege (1)
  Albert Caramoy (1)
  Andreas Kersten (2)
  Janina Luberichs-Fauser (2)
  Katharina Zilkens (2)
  Dirk Müller (3)
  Bernd Kirchhof (1)
  Sascha Fauser (1)
  
  1. Department of Vitreo-Retinal Surgery, University of Cologne Center of Ophthalmology, 50924, Cologne, Germany
  2. Ambulantes Operationszentrum Neuss, Neuss, Germany
  3. Institute for Health Economics and Clinical Epidemiology, University Hospital Cologne, Cologne, Germany
  
• ISSN：1435-702X

文摘

Purpose To identify preference of treatment regimen in patients with anti-VEGF therapy for neovascular age-related macular degeneration (AMD) in real life. Methods A cross-sectional study was conducted in 200 patients receiving ranibizumab therapy on a pro re nata regimen with monthly controls. One hundred and twenty-four patients were recruited in a tertiary health care clinic, and 76 patients were recruited in a private practice. Patients were asked to respond to a 14-item questionnaire covering items such as treatment burden and preference for treatment: either monthly injections or pro re nata. Results Mean time under anti-VEGF treatment was 33.7 months, and the mean number of intravitreal injections was 17.7. Despite a high treatment burden in 60.3?% of patients, there was an acceptance rate for monthly examinations or injections of 93?%. The proportion of patients who favoured a PRN regimen was 53.0?%, whereas 37.9?% of patients favoured continuous injections. Major concern was recurrent disease activity in 54.5?%. Conclusion We identified two groups of patients of considerable size who would prefer either monthly injections or as-required. Overall, there was a high acceptance rate despite a high treatment burden. Nevertheless, efforts should be undertaken to improve examination and injection procedures and to consider the patient’s preference for a treatment regimen.